Skip to Main Content

Paper Details

A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
Onco Targets Ther
2
2021
Author NameAffiliation
Ting XuDepartment of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center
Najat C DawUniversity of Texas MD Anderson Cancer Center
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center
Funda Meric-BernstamUniversity of Texas, MD Anderson Cancer Center
Funda Meric-BernstamThe Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center
  • 1 - 5

Datasets

Release 1.2